Autoimmune hemolytic anemia
MONDO:0020108Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in hemolytic anemia.
Also known as: AHA, AIHA, Anemia, Hemolytic, Acquired Autoimmune, autoimmune haemolytic anemia, autoimmune hemolytic anemia, acquired autoimmune hemolytic anaemia, acquired autoimmune hemolytic anemia, anaemia hemolytic autoimmune
115 clinical trials for this condition and its sub-types, 49 tagged with Autoimmune hemolytic anemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Autoimmune hemolytic anemia
-
Autoimmune hemolytic anemia, warm type 29 trials
-
Evans syndrome 19 trials
-
Autoimmune hemolytic anemia, cold type 2 trials · 15 incl. sub-types
2 sub-types
- Cold agglutinin disease 14 trials
- Paroxysmal cold hemoglobinuria 0 trials
-
Neonatal autoimmune hemolytic anemia 0 trials
-
New hope for rare blood disorder: drug trial targets anemia
Disease control OngoingThis phase 3 trial tests a drug called ianalumab against a placebo in 90 adults with warm autoimmune hemolytic anemia (wAIHA) who have already tried at least one treatment without success. The goal is to see if ianalumab can raise hemoglobin levels and keep them stable for at lea…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThis study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …
Phase 2/3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Cheap drug combo may tame tough anemia
Disease control CancelledThis trial tests a combination of two drugs, sirolimus and all-trans retinoic acid (ATRA), for people with autoimmune anemia that has not responded to standard treatments. Autoimmune anemia occurs when the immune system attacks red blood cells, causing fatigue and other symptoms.…
Phase 4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a week of antibiotics stop joint infections after replacement surgery?
Disease control By invitation onlyThis study tests whether taking a 7-day course of oral antibiotics after hip or knee replacement surgery can prevent joint infections in patients at higher risk due to conditions like obesity, diabetes, or autoimmune disease. About 4,600 participants will receive one of three ant…
Phase 4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental CAR-T therapy targets tough autoimmune conditions
Disease control PausedThis early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…
Early phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill could help patients with rare blood disorder
Disease control OngoingThis study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goa…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for warm AIHA: drug trial targets blood cell destruction
Disease control OngoingThis study tests a drug called HMPL-523 (Sovleplenib) in people with warm antibody autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. About 111 adults will receive either the drug or a placebo to see if it improves hemoglobin levels and cont…
Phase 2/3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a cancer drug tame a blood disorder?
Disease control OngoingThis phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThis phase 2 trial tests whether isatuximab can help people whose blood cell counts stay low after a stem cell transplant for blood cancer. The study enrolls 12 adults whose disease is in remission but who have developed immune-related blood cell deficiencies. Participants receiv…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New blood treatment could block zika in transfusions
Disease control OngoingThis study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…
Phase 3 • Sponsor: Cerus Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug hope for rare blood disorder that causes anemia in cold weather
Disease control OngoingThis phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce an…
Phase 2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Drug access program offers hope for rare blood disorder patients
Disease control Expanded access (paused)This program provides continued treatment with nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants receive the drug by IV infusion every 2 or 4 weeks. The goal is to keep their hemoglobin levels…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Study withdrawn: extended access to fostamatinib for transplant patients never launched
Disease control CancelledThis study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused By invitation onlyThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New registry aims to unlock secrets of rare blood disorder
Knowledge-focused OngoingThis study is a registry that collects information from about 429 adults with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS), a rare condition where the immune system attacks red blood cells in cold temperatures. Researchers will track symptoms, treatments, compl…
Sponsor: RECORDATI GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused By invitation onlyThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC